Ra’anana, Israel-based Inspira expects its Liby system, currently under development, to be submitted to the FDA for regulatory approval during the first half of 2023. ECMO technology pumps, oxygenates and removes carbon dioxide from blood for patients whose lungs can’t provide sufficient end-organ oxygenation.
The company designed Liby as a next-generation ECMO system with the intention of making it the first system designed for integration with the company’s non-invasive HYLA blood sensor technology, according to a news release. HYLA, in conjunction with Liby, could allow for real-time and continuous monitoring of patient condition to alert physicians of immediate signs of changes in a patient’s clinical condition, the company said.
Liby features a large touchscreen and novel colorful graphical representation to increase the visibility, scope and functionality of data displayed to the medical staff. It has a small footprint and lightweight characteristics as well as a rapid-style aerospace-grade aluminum structure to be both lightweight and highly durable with a long battery life.
The company said the design of Liby reflects the design of its flagship ART system, particularly through its business model designed to generate recurring revenues based on consumable sales of its single-use disposable kit. The single-use kit represents an important part of the system’s design with an aim toward reducing setup time and associated medical-care costs.
“The Liby system is intended to target one of three market segments within Inspira Technologies product scope,” Inspira Technologies CEO Dagi Ben-Noon said in the news release. “The Liby system is expected to introduce the next generation of ECMO within intensive care units (ICUs), due to its practical advantages, designed to improve durability, patient mobility both within the hospital or via ambulance, and ease of use. I believe that these are important advantages for medical teams within over-crowded ICUs, targeting to improve patient outcomes.”